Haplotype Targeting in Heart Failure Using a Biased Ligand β-blocker

Ian A. Carroll,[1,2,3] Dobromir Slavov,[1,2] Eric R. Jonas,[1] Wayne A. Minobe,[1] Lori A. Walker,[1]

Amrut V. Ambardekar,[1,2] Timothy A. McKinsey,[1,2] Ammon D. Knaupp,[4] Donghwa Kim,[5]

Stephen B. Liggett,[3,5,6] Michael R. Bristow[1,2,3,7,*]

[1]Department of Medicine (Cardiology) University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA

[2]Section of Pharmacogenomics, University of Colorado Cardiovascular Institute, Boulder (80309) and Aurora (80045) CO, USA

[3]Genvara Biopharma, Westminster, CO 80021 USA

[4]BYU Genomic and Bioinformatic Center, Provo UT 84602, USA

[5]Department of Medicine and Center for Personalized Medicine, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA

[6]Department of Molecular Pharmacology and Physiology, University of South Florida Morsani College of Medicine, Tampa, FL 33612, USA

[7]Lead Contact

*Corresponding Author

Conflict of Interest Statement
M.R.B., I.A.C. and S.B.L. own stock in Genvara Biopharma (current sponsor of bucindolol) and are Inventors on a patent covering some of the manuscript's content; M.R.B. and I.A.C. have partial salary support from Genvara; MRB is Chief Science and Medical Officer and Chairman of Genvara. M.R.B. and S.B.L. are Principal Investigators on a submitted NIH grant related to this work.

ABSTRACT

ADRB1 and *ADRB2,* encoding β_1- and β_2-adrenergic receptors (ARs), each contain 2-SNP haplotype variants capable of influencing agonist- or biased ligand-induced receptor internalization that uncouples canonical signaling and initiates EGFR/ERK1/2 cardioprotection. In two heart failure (HF) clinical trial substudies we investigated effects of internalizing vs. internalization-resistant *ADRB1*/*ADRB2* haplotypes on clinical responses to the biased ligand β-blocker bucindolol vs. placebo or the nonbiased β_1-antagonist metoprolol. ERK1/2 activation was also measured, in haplotyped isolated human heart preparations. In subjects with ≥3 internalizing *ADRB1*+*ADRB2* haplotypes (18% subcohort) placebo treatment was associated with fewer clinical events compared to internalization-resistant counterparts (Odds Ratio (OR) 0.39, 95% CI (0.27,0.55)). Bucindolol vs. placebo lowered event rates in subjects with ≥3 (70% subcohort) internalization-resistant haplotypes vs. their counterparts, OR 0.49 (0.41,0.58). In subjects with all 4 haplotypes internalization-resistant (25% subcohort), bucindolol vs. placebo reduced time to first event rates by 62.3±17.5% ($P < 0.01$, 1.68±0.34 fold > all-haplotypes parent population and additive to 1.92±0.58 fold when *ADRB1* contained Arg389). The same bucindolol vs. placebo pattern was observed for NT-proBNP reduction vs. metoprolol. Bucindolol but not metoprolol activated ERK1/2 signaling in isolated ventricular preparations with ≥3 internalization-resistant haplotypes. Haplotype targeting, long a goal in pharmacogenetics, is feasible in HF.

Key Words: Haplotypes; Beta Adrenergic Receptors; Single Nucleotide Polymorphisms; Heart Failure; Pharmacogenetics; Racial Genetic Variation; MAP Kinase ERK1/2; Biased Ligands.

INTRODUCTION

Human cardiac myocytes contain 3 types of β-adrenergic receptors (β-ARs), with β_1-ARs dominating but β_2-ARs also potentially involved in the regulation of cardiac function and capable of mediating pathologic effects of chronic adrenergic stimulation in the failing heart.[1,2] In heart failure (HF) increased norepinephrine (NE) signaling contributes to myocardial pathologic remodeling, the inhibition of which results in the beneficial effects of β-blockers in subjects with reduced ejection fraction (HFrEF, LVEF <0.40).[1,3,4] Although chronically increased cardiac adrenergic drive has a net myopathic effect on the myocardium[1,4] including predisposing to arrhythmias,[5] certain cellular mechanisms can counter these adverse effects. The most obvious of these are β-AR desensitization and/or downregulation that diminish adrenergic signaling through canonical cAMP/PKA and CaMKII pathways.[1] In addition, for both β_1-[6-8] and β_2-ARs[9-11] desensitization also includes signaling through an alternative, EGFR/ERK1/2 cardioprotective pathway consisting of receptor phosphorylation, binding to β-arrestins, endocytic internalization and endosomal trafficking to fates that include lysosomal degradation.[7,8] In this series of events receptor internalization is a critical step, as inhibitors of endocytic vesicle formation block EGFR transactivation and ERK1/2 phosphorylation.[10,12] β-adrenergic agonists classically activate this pathway,[6-8, 10-12] but with some differences[13] so can β-blocker "biased ligands".[14-17]

On short-term (≤1 hour) exposure to agonists some β-AR polymorphic variants differ from their counterparts in their abilities to desensitize, internalize, and/or traffic intracellularly. For *ADRB1* the more prominently desensitizing and internalizing β_1-AR variant is Gly49,[18] which compared to Ser49 also exhibits differences in subsequent intracellular trafficking[19,20] that are present in both the Arg389 and Gly389 haplotypes.[20] In addition, when in a Gly389 haplotype, Gly49 is associated with greater agonist-induced ERK1/2 phosphorylation.[21] For β_2-ARs, the Gln27Arg16 haplotype exhibits rapid agonist desensitization *in vivo* compared to other haplotypes,[22] and rapidly and substantially desensitizes[23] and internalizes[,23-25] on agonist exposure in cells transfected with the original human β_2-

AR cDNA containing the Gln27Arg16 haplotype.[26] Thus both *ADRB1* and *ADRB2* N-terminus nonsynonymous SNPs can affect internalization.

The *ADRB1* position 49 and the *ADRB2* position 27 or 16 polymorphisms do not influence signal transduction efficiency.[18-20,24] However, the *ADRB1* Ser49Gly polymorphism is in strong linkage disequilibrium (LD) with the nonsynonymous C-terminus SNP Arg389Gly,[27] whose encoded variants have major effects on signal transduction capacity and agonist affinity.[28,29] The *ADRB2* position 27 and 16 variants are also in tight linkage disequilibrium.[27] *ADRB1* 389/49 haplotypes can therefore encode receptors with greater (Arg389 containing) or lesser (Gly389) signaling capacity that internalize to a greater (Gly49) or lesser (Ser49) extent in the presence of agonists or potentially to biased ligands, while the *ADRB2* Gln27Arg16 vs. other encoded haplotypes have the potential for more vs. less internalization.

In the MAP-MI study[27] we recently reported that the *ADRB1* Arg389Gly49 haplotype is associated with a reduction in incident ventricular fibrillation (VF) in acute myocardial infarction. There was also evidence of a VF protective signal in subjects with the *ADRB2* Gln27Arg16 haplotype.[27] These findings were interpreted as potentially due to EGFR/ERK1/2 cardioprotective pathway signaling[6,12] that internalization of both β_1-,[8,12,30] and β_2-ARs[10,31,32] are known to activate when occupied by an agonist, in this case NE. An earlier study had found that the *ADRB1* Gly49 polymorphism, in genotyping studies typically present only as the Arg389Gly49 haplotype, is associated with improved survival in dilated cardiomyopathy patients, also suggesting a myocardial protective mechanism.[33] Since HFrEF human ventricles contain 35-40% β_2-ARs that are coupled to inotropic and pro-arrhythmic pathways and when overexpressed in model systems to a cardiomyopathy,[1,2] there is also a rationale for β_2-AR internalization affecting outcomes in HFrEF.

Here we test the hypothesis that internalization or internalization-related effects of *ADRB1* and *ADRB2* common haplotype variants influence clinical outcomes in HFrEF patients treated with placebo,

the biased ligand β-blocker bucindolol, or the nonbiased β-blocker metoprolol succinate. The 2 clinical trial cohorts investigated[29,34] were haplotyped for *ADRB1* and *ADRB2* variants, and one of them (BEST Trial Adrenergic Receptor Polymorphism substudy[29,35]) included populations with substantial racial heterogeneity that affects haplotype frequency and thus provides an opportunity for internal confirmation by investigating separate genetic subpopulations. The presented data support the utility of pharmacogenetic targeting of protein haplotypes,[36] something that has long held promise[37,38] but has been difficult to implement.

RESULTS

BEST Adrenergic Receptor Polymorphism Substudy

This 1040 patient pharmacogenomics substudy[29] of the BEST trial[35] investigated advanced HFrEF patients (NYHA Class III-IV HF, LVEFs ≤0.35) with elevated plasma NE levels (**Table S1, Supplemental Material**) randomized to treatment with placebo or the nonselective β_1-, β_2-AR blocker/biased ligand bucindolol. Eligible subjects gave written informed consent for the parent trial[35] and as an option for peripheral blood DNA extraction and genotyping in the substudy.[29] Further trial details are in Methods.

Allele, Genotype, and Haplotype Frequencies; Linkage Disequilibrium

A description of the formatting and terminology used for genotypes, haplotypes and diplotypes is in **Table S2** and the first paragraph of **Supplemental Material**. Allele frequencies of *ADRB1* and *ADRB2* polymorphisms by Black and non-Black self-identified races are in **Table S3**, and are similar to those previously reported for European- vs. African-Ancestry in the BEST substudy.[39] Blacks have higher minor allele frequencies for *ADRB1* Gly389 and Gly49, and for *ADRB2* 16Arg. *ADRB2* 27Glu is lower frequency in Blacks.

Genotypes and theoretical vs. identified diplotypes are in **Table S4.** For both *ADRB1* and *ADRB2*, of 10 theoretical diplotypes only 6 were identified; diplotypes with *ADRB1* Gly389Gly49 or *ADRB2*

Glu27Arg16 haplotypes are missing. In each gene identified diplotypes consist of 3 homozygotes, 2 single heterozygotes, and 1 double heterozygote. There is strong LD between *ADRB1* positions 389 and 49 polymorphisms, as well as among *ADRB2* positions 27, 16 and 164 (**Table S5**); the latter polymorphism was very low frequency (MAF=0.012, **Table S3**) and was not further investigated. The absence of *ADRB1* Gly389Gly49 and *ADRB2* Glu27Arg16 haplotypes was confirmed by long-read DNA sequencing conducted in 26 *ADRB1* 389/49 and 50 *ADRB2* 27/16 double heterozygotes. **Table S6** also gives haplotypes by sex within race categories, where there is no difference between sexes within either race category.

Diplotype and haplotype frequencies by race classification are in **Tables 1** and **S6**, respectively. Arg389Gly49 and Gly389Ser49 haplotypes are more prevalent in Blacks, while the major allele haplotype Arg389Ser49 is more prevalent in non-Blacks (**Table S6**). For *ADRB2* Gln27Gly16 as well as Gln27Arg16 are more prevalent in Blacks. The internalizing haplotypes Arg389Gly49 (*ADRB1*) and Gln27Arg16 (*ADRB2*) are respectively 1.71 (P<0.0001) and 1.21 (P=0.004) fold more frequent in Blacks vs. non-Blacks. Internalization-resistant haplotypes are more prevalent in non-Blacks compared to Blacks, by 1.14 (P <0.0001) and 1.15 (P=0.004) fold in *ADRB1* and *ADRB2*, respectively (**Table S6**).

For *ADRB1* diplotypes (**Table 1**), any that contain at least 2 total glycines in positions 389 plus 49 are more prevalent in Blacks, while the Arg389Ser49 homozygous diplotype is more common in non-Blacks. The Arg389Gly49 homozygous diplotype is 2.34 fold more common in Blacks (P =0.012), as is the homozygous Gly389Ser49 diplotype (by 2.43 fold, P <0.0001).

Baseline Characteristics

Baseline characteristics by diplotype, race and treatment group are in **Table S1**. For diplotypes the main differentiating characteristic is race (**Tables S1** and **S6)**. In comparison to non-Blacks, Blacks are 5 years younger and have higher resting heart rates and systolic blood pressures. There are no differences in baseline characteristics between treatment groups.

β-adrenergic Receptor Haplotype Internalization Potential Affects Clinical Outcomes

Clinical Events in Internalizing vs. Internalization-resistant Haplotypes

As an initial test of the hypothesis that *ADRB1* and *ADRB2* haplotypes with different internalization potential affect clinical outcomes, in placebo- and bucindolol-treated subjects in the BEST substudy unadjusted odds ratios (ORs (95% C.I.s)) for first clinical event rates were compared between defined {*ADRB1* + *ADRB2*} haplotype internalizing vs. internalization-resistant groups. The index internalizing haplotypes were *ADRB1* Arg389Gly49 and *ADRB2* Gln27Arg16 as tabulated in {*ADRB1* + *ADRB2*} diplotype combinations, which were compared to all other diplotype combinations (see classification nomenclature, **Table S2)**. In the classification descriptors "number" is the sum of the *ADRB1* + *ADRB2* haplotypes in the diplotype combination, "D" (double) indicates that at least 1 defined haplotype is present in both genes, "I" is internalizing, and "IR" is internalization-resistant.

Figures 1-3 (all-LVEF cohort) and **S1-S3** (cohort restricted to baseline LVEFs of ≥0.20) are forest plots of the between-haplotypes ORs for 7 clinical endpoints that include the primary endpoints for the BEST and GENETIC-AF substudies, respectively time to all-cause mortality or cardiac transplantation (ACM/Tx)[28] and time to first atrial fibrillation or flutter (AF/AFL/ACM).[34] To provide a robust statistical analysis as well as to correct for possible confounding variables, a covariate adjusted structural equation model (SEM) endpoint analysis is provided in **Table S7** where clinical events are modeled against increasing numbers of internalization-resistant haplotypes from 0 to 4. All analyses are constructed from the first clinical events in subjects who had complete *ADRB1* and *ADRB2* genotyping. In **Figures 1-3** and **S1-S3** {*ADRB1* + *ADRB2*} diplotype combinations are organized by 3 sections or tiers based on the total number of internalizing {*ADRB1* + *ADRB2*} index haplotypes. **Tier 1** is 3-4 copies of *ADRB1* AND *ADRB2* internalizing haplotypes ("Double-Internalizing", **≥3DI**); **Tier 2** has 2 copies of internalizing haplotypes ("Incompletely Internalizing", **2I**); and **Tier 3** has 0-1 copies of internalizing (3-4 internalization-resistant) haplotypes ("Double Non- internalizing", **≥3DIR**). The

sequence of presentation is placebo treated patients (**Figures 1 and S1**), bucindolol patients (**Figures 2 and S2**), and bucindolol vs. placebo treatment effects (**Figures 3 and S3**). ORs in **Figures 1/S1** and **2/S2** are generated by comparing the haplotype pairs in Column 1 to all other haplotype pairs not defined in Column 1, and treatment effect ORs (**Figures 3/S3**) are based on bucindolol vs. placebo event ORs.

Placebo Treatment in Subjects with {ADRB1 + ADRB2} Internalizing vs. Internalization-resistant Haplotypes is Associated with Lower Clinical Event Rates

In the All-LVEF cohort the endpoint analysis for placebo treatment (**Figure 1**) indicates that subjects within **Tier 1 (≥3DI)** have OR point estimates to the left of the line of identity, ranging from 0.29 (0.12, 0.68) for cardiovascular mortality or heart failure hospitalization (CVM/HFH) to 0.48 (0.23, 1.00) for cardiovascular hospitalization (CVH). The mean for all 7 endpoints is 0.39 (0.27, 0.55). In contrast, for the **Tier 3 (≥3DIR)** subjects ORs are to the right of the identity line, between 1.45 (0.88, 2.39) for CVM and 1.78 (1.22, 2.58) for CVH, mean 1.64 (1.46, 1.84). The **Tier 2 (2I),** subjects position between **Tiers 1** and **3**, slightly to the left of identity, with a mean OR of 0.76 (0.66, 0.88). By an aggregate analysis of all 7 endpoints, **Tier 1** event rates and their ORs are significantly different from **Tier 3** (P=0.005). The less severe LV dysfunction cohort (LVEF ≥0.20) placebo forest plot (**Figure S1**) is very similar to the All-LVEF cohort, with a Tier 1 vs Tier 3 aggregate OR difference also P=0.005.

The SEM analysis in the All-LVEF cohort, adjusted for both dependencies between endpoints and direct effects of 13 covariates, confirms an increase in the placebo event rate slopes progressing from 0 to 4 internalization-resistant haplotypes in **Tier 1** through **Tier 3 (Table S7)**. All 7 endpoints in both cohorts have positive individual slopes, indicating increases in event likelihood as the number of internalization-resistant haplotypes is increased. Five of the 7 endpoints in the All-LVEF cohort satisfy P <0.05, with 4 of 7 in LVEF ≥0.20. By Likelihood Ratio Testing the slopes show no evidence of heterogeneity (χ^2 P =0.58, 0.78 for All-LVEF, LVEF ≥0.20 respectively), indicating that the effect of

internalization does not differ across endpoints. A follow-up SEM with equality constraints for this component of the structural model yields a significant positive effect of internalization tier on event likelihood across all 7 endpoints (P = 0.002 and 0.022 for the All-LVEF and ≥0.20 cohorts, respectively) (**Table S7**).

Bucindolol Treatment is Unaffected by Haplotype Internalizing Potential

In contrast to placebo treatment, the bucindolol forest plot OR point estimates for the All-LVEF (**Figure 2**) and LVEF ≥0.20 cohorts (**Figure S2)** exhibit minimal tendency for departure from the line of identity, with a nonsignificant SEM analysis (**Table S7**). In contrast to placebo, no estimated effect of increasing internalization-resistant haplotypes is statistically significant (**Table S7)**.

Bucindolol vs. Placebo Treatment Effects are Inversely Related to Haplotype Internalizing Potential

Figures 3 and **S3** contain between-treatment group ORs within internalization haplotype tiers, and demonstrate a pattern commensurate with the within-placebo and -bucindolol subjects in **Figures 2** and **S2**. In both the All-LVEF (**Figure 3**) and LVEF ≥0.20 (**Figure S3**) cohorts the **≥3DI Tier 1** ORs, although statistically nonsignificant, are to the right of the identity line, while in **Tier 3** the **≥3DIR** ORs are <1.0 with the majority (5 of 7 in **Figure 3**, all 7 in **Figure S3**) statistically significant. The SEM analysis (**Table S7**) difference between the placebo and bucindolol group slopes indicates consistent treatment effects across all endpoints in both LVEF cohorts. Bucindolol minus placebo slope values vary from -0.11 (HFH) to -0.27 (ACM/Tx) in the All LVEF Cohort, and -0.22 (AF/AFL/ACM) to -0.38 (ACM/Tx) in LVEF ≥0.20, indicting the bucindolol treatment effect is consistently against the presence of internalizing and in favor of internalization-resistant haplotypes. The All 7 Endpoints interaction P values are statistically significant in both cohorts, P=0.048 (All LVEF) and P=0.003 (LVEF ≥0.20), respectively indicating the slopes of the placebo and bucindolol groups are different (**Table S7**), and that

bucindolol treatment negates the deleterious effects of increasing numbers of internalization-resistant haplotypes observed in placebo-treated subjects.

ADRB1 and ADRB2 Haplotypes Are Associated with Similar Internalization to Non-internalization Dose-Responses

Placebo Treatment

Figures S4-S6 contain All-LVEF cohort data for the internalizing *ADRB1* Arg389Gly49 haplotype held constant at 1 or 2 copies and paired with decreasing copies (from 2 to 0) of the *ADRB2* internalizing, Gln27/Arg16 haplotype. ORs are calculated and plotted as for **Figures 1-3**, representing an internalizing to internalization-resistant *ADRB2* haplotype dose-response for the 7 clinical endpoints. Within each clinical endpoint there is a progressive increase in ORs for all 7 endpoints as the copy number of *ADRB2* Gln27Arg16 decreases, from an OR range of 0.15 − 0.47 (mean 0.28±0.12) for 2 copy to 1.03 − 1.59 (mean 1.34±0.19) for 0 copies (P=0.016). For the 7 clinical endpoints, 8 of the 14 ORs in the Gln27Arg16 2 or 1-2 copy groups are statistically significantly reduced (upper bound <1.00), with none changed in the remaining 3 categories with fewer copy numbers. The converse, haplotype downtitration of *ADRB1* Arg389Gly49 in the presence of constant, 1-2 copies of *ADRB2* Gln27Arg16 (**Figure S7)** yields similar data.

Bucindolol Treatment

In contrast, the internalizing to internalization-resistant haplotype dose-response is not present in patients treated with bucindolol (**Figures S5, S8)**. In **Figure S5,** with downtitration of the internalizing *ADRB2* haplotype Gln27Arg16, ORs are on either side and close to the 1.0 identity line with none statistically significant. The downtitration of the *ADRB1* internalizing haplotype (**Figure S8**) reveals a slightly different pattern, with 2 copies of Arg389Gly49 demonstrating a lower OR (ranging from 0 to 0.73, mean 0.32±0.29) than all other copies in all 7 endpoints. Also, for mortality dominant endpoints (CVM, ACM/Tx, ACM), haplotypes with 0 copies of Arg389Gly49 have ORs consistently >1.0 (range

1.25-1.68, mean 1.52±0.16). These 2 deviations from Gln27Arg16 downtitration are likely due to the respective favorable and relatively unfavorable impacts of bucindolol in subjects with *ADRB1* Arg389Arg and Gly389 genotypes.[29]

Bucindolol vs. Placebo Treatment Effects

Bucindolol vs. placebo treatment effects with downtitration of internalizing haplotypes (**Figures S6** and **S9**) generally indicate an overall progressive decrease in ORs in all endpoints, or the opposite pattern to that for placebo in **Figures S4** and **S7**. The one exception is consistently low ORs for 2 copy Arg389Gly49 in all 7 endpoints, again likely due to the favorable impact of the *ADRB1* Arg389Arg genotype on bucindolol treatment effects.[30]

Hazard Ratios for Time to Clinical Events, Internalizing vs. Internalization-resistant Haplotypes

Placebo or Bucindolol Treatment in Internalizing vs. Internalization-resistant Haplotypes

Clinical event hazard ratios (HzRs) differ from odds ratios by incorporating the element of time, which can increase the sensitivity for detection of treatment effect differences. For placebo treated patients in the BEST substudy All-LVEF cohort, **Figure S10** contains time to first event curves and HzRs comparing ≥2 Double Internalizing (**≥2DI**, 1-2 copies of *ADRB1* Arg389Gly16 AND 1-2 copies of *ADRB2* Gln27Arg16) to subjects with all other (≥2 Not Double Internalizing, **≥2IR**) haplotypes, for 4 of the clinical endpoint ORs plotted in **Figures 1-3** and **S1-S3**. In all 4 endpoints placebo-treated subjects with **≥2DI** haplotypes exhibit progressive, favorable separation in the Kaplan-Meier (K-M) curves compared to **≥2IR** haplotypes, with HzRs ranging from 0.62 (0.40, 0.97) to 0.69 (0.48, 1.00). **Figure S11** contains the same comparisons for bucindolol-treated patients in the All-LVEF cohort, where curve separation does not occur for **≥2DI** vs. **≥2IR**subjects; HzRs are near 1.0 for all 4 endpoints, and event rates are similar to the **≥2DI** placebo curves in **Figure S10**.

Bucindolol vs. Placebo Treatment Effects in Maximum Internalization-resistant Haplotypes

As an extreme evaluation of the consequences of internalization-resistant *ADRB1* and *ADRB2* haplotypes on treatment effects, in the LVEF ≥0.20 cohort **Figure 4** shows bucindolol vs. placebo time to first event curves for "Maximum Double Internalization-resistant" (**4DIR**) *ADRB1* and *ADRB2* combination diplotypes (2 copies of an *ADRB1* Ser49 containing haplotype AND 2 copies of an *ADRB2* non-Gln27Arg16 diplotype). HzRs (95% C.I.s) range from 0.17 (0.05, 0.56) for ACM/Tx (substudy primary endpoint) to 0.53 (0.33, 0.84) for CVH.

ADRB1 and ADRB2 Haplotype Effects Are Equivalent in Black and Non-Black Race

As shown in **Tables 1** and **S1**, Black vs. other races exhibits differences in common genetic variation within β-ARs, as in other neurohumoral[39] and non-neurohumoral systems.[40] **Figure 5** consists of bucindolol vs. placebo time to event curves in the All-LVEF cohort by Black or non-Black racial categories for the high prevalence composite endpoints of time to first CVM/HFH and CVH, in subjects with Double Internalizing (**≥2DI)**, and Not Double Internalizing (**≥2IR)** haplotypes. For **≥2DI** subjects due to favorable effects in placebo-treated subjects there is no evidence of a bucindolol treatment effect in either Blacks or non-Blacks. In contrast, in **≥2IR** subjects for both endpoints there is evidence of a treatment effect, with little or no difference in HzRs between Black and non-Black subjects (HzRs ranging from 0.64 (0.39, 1.06) for CVH in Blacks to 0.76 (0.61, 0.96) for CVH in non-Blacks, nearly identical HzRs in CVM/HFH). These data indicate that within the **≥2IR** haplotype phenotype there are no differences between Blacks and non-Blacks for enhancement of bucindolol treatment effects.

The haplotype dose response progressing from ≥2 Double Internalizing to ≥2 Internalization-resistant in placebo treated patients (**Figures 1, S1**) is observed in both Blacks and non-Blacks (**Figure S12**). For both groups the 7 endpoint ORs in **Tier 1**, **≥3DI** subjects are consistently to the left of the line of identity, **Tier 3**, **≥3DIR** point estimates are to the right of 1.0, and **2I** Incompletely Internalizing estimates are intermediate, positioned around 1.0.

GENETIC-AF DNA Substudy

Internalizing/Internalization-resistant Haplotypes

The GENETIC-AF trial, a Phase 2 trial that randomized HFrEF and HFmrEF (HF with LVEF 0.40-0.49) patients to bucindolol or metoprolol succinate who were *ADRB1* Arg389Arg genotype (N=267) and at risk for developing recurrent AF,[34] included a voluntary DNA Bank substudy. These 138 substudy patients were subsequently genotyped for *ADRB1* Ser49Gly and *ADRB2* position 27 and 16 polymorphisms, with their baseline characteristics by *ADRB1* or *ADRB2* diplotype in **Table S8**. The small sample size precluded assessment of clinical events, but the trial included peripheral venous plasma NT-proBNP and NE biomarker measurements at baseline (pre-randomization to bucindolol or metoprolol succinate) and at 4, 12 and 24 weeks (trial end) of efficacy follow-up.[34] The genotypes, haplotypes and diplotypes are in **Table S9.** Subject diplotypes were divided by {*ADRB1* + *ADRB2*} diplotype combination into **≥2DI** and **≥2IR** groups as for the BEST substudy, and biomarker changes were assessed in the 2 treatment groups (**Figure 6**, **Tables S10-S13**). Biomarkers were also analyzed in **4DIR** haplotype subjects (**Tables S10-S13**).

Baseline characteristics within *ADRB1* or *ADRB2* diplotype cohorts (**Table S8**) or in the treatment arms do not differ meaningfully. NT-proBNP is a biomarker for both AF and HF,[34] and thus is a suitable surrogate for GENETIC-AF's primary endpoint of time to symptomatic AF/AFL/ACM in a HF population. In bucindolol-treated subjects with maximum internalization-resistant, **4DIR** haplotypes (**Table S10**), at 4, 12 and 24 weeks NT-proBNP is decreased by respective amounts of 737±312 pg/ml (mean±sem, P= 0.009), 493±329 pg/ml (P=0.15) and 778±266 pg/ml (P= 0.005). In contrast, metoprolol treated **4DIR** patients (**Table S11**) exhibit no statistically significant changes at any timepoint (**Table S11**). For *ADRB1* + *ADRB2* **≥2DI** haplotypes (**Tables S10, S11)**, neither bucindolol nor metoprolol treated subjects exhibit changes in NT-proBNP at any timepoint (**Figure 6A, 6B, Tables S10, S11**). In contrast, in **≥2IR** haplotype subjects treated with bucindolol NT-proBNP is reduced from a baseline of 1364±1494 pg/ml by 252±242 pg/ml (mean±sem, P=0.004 vs. baseline), 361±158 pg/ml (P=0.043), and

380±143 pg/ml (P=0.003) at 4, 12 and 24 weeks respectively (**Figure 6A, Table S11**). Metoprolol-treated patients with **≥2IR** haplotypes have no significant changes from baseline (**Figure 6A, B**; **Table S11).**

NE measurements are in **Figure 6C, D** and in **Tables S12** and **S13**. For bucindolol-treated subjects with **4DIR** haplotypes the pattern is similar to NT-proBNP; there are statistically significant reductions at 4, 12 and 24 weeks (**Table S12**). Also similar to NT-proBNP, in **4DIR** haplotypes there are no reductions in NE at any timepoint in the Metoprolol Arm (**Table S13**). Results for **≥2DI**, Double Internalizing haplotypes are also similar to NT-proBNP, with no significant changes at any timepoint in either the bucindolol or metoprolol arms (**Figure 6C, D**; **Tables S12 and S13**, respectively). The ≥**2IR,** bucindolol group (**Figure 6C, D**; **Table S12**) results are also similar to those for NT-proBNP, with statistically significant reductions at 4, 12 and 24 weeks. In the metoprolol arm ≥**2IR** subjects there are no changes in NE at any timepoint. (**Figure 6C, D**; **Table S13**).

Pre-randomization Treatment with Carvedilol vs. Other β-blockers Affects NT-proBNP Responses

Prior to randomization all patients were receiving a commercially available HF β-blocker (**Table S14**), and baseline NT-proBNP and NE biomarker levels were drawn at randomization prior to their discontinuation and uptitration of study medication.[34] Carvedilol was being administered to 33 subjects, a metoprolol preparation to 59, bisoprolol to 37, and 1 patient was receiving nebivolol (**Table S14**). β-blocking doses are not different between carvedilol and other β-blockers converted to carvedilol equivalents, by either total mg dose/d or mg/kg/d, or between the **≥2DI** and **≥2IR** categories (mg/d, P=0.13; mg/kg/d, P=0.29). With the possible exception of LVEFs (slightly higher in the Not Carvedilol **≥2IR** group), baseline characteristics between the 2 internalizing haplotype groups do not differ in any clinically meaningful way (**Table S14**).

NT-proBNP and NE data are in **Figure S13**. The NT-proBNP baseline values are not different between Carvedilol and "Not Carvedilol" groups, in any of the treatment/haplotype subgroups.

Consistent with data in **Figure 6A**, with bucindolol treatment only subjects with **≥2IR** haplotypes have a reduction in NT-ProBNP (**Figure S13A, B**), but the pattern is different in the Carvedilol vs. Not Carvedilol groups. For Carvedilol the NT-proBNP decrease in the **≥2IR** group is slower to develop than in the Not Carvedilol group, and is statistically significant only at week 24 (34% reduction, P=0.007). In contrast, in the Not Carvedilol group NT-proBNP is reduced at 4 (P=0.008) and 24 weeks (P=0.044). In addition, metoprolol arm **≥2IR** subjects who received pre-randomization carvedilol have a progressive increase in NT-proBNP, which becomes statistically significant at 24 weeks (P=0.009 vs. Not Carvedilol **Figure 13A, B**). For NE, reductions also occur only in bucindolol arm **≥2IR** subjects (**Figure S13A, B**), but in contrast to NT-proBNP the effect in subjects with prior carvedilol treatment begins at the first timepoint. For metoprolol treatment, there is no change in NE in either the Carvedilol or Not Carvedilol group.

Expansion of the Bucindolol Pharmacogenetic Target Population and Efficacy by the Inclusion of *ADRB1*, *ADRB2* Internalization-resistant Haplotypes

For bucindolol vs. placebo treatment effects, efficacy enhancement by internalization-resistant β-AR haplotypes in the BEST substudy creates the potential for enlarging bucindolol's pharmacogenetically targeted population beyond *ADRB1* Arg389Arg.[29,34] Also, within the expanded target population there is the potential for subgroups yielding treatment effects superior to *ADRB1* Arg389Arg.[29,34] For the LVEF ≥0.20 cohort, treatment effects for all listed pharmacogenetic groups (**Table S15, columns 2-8**) exceed that for the All-Genotypes parent index cohort (Column 1), at a significance level of at least P <0.05. In addition, in 4 of the 6 internalization-resistant diplotype-containing subgroups (Columns 3-8) treatment effects statistically exceed those of the Column 2 *ADRB1* Arg389Arg genotype index pharmacogenetic enhancement subgroup, and all 6 are quantitatively greater. Moreover, the combined *ADRB1* AND *ADRB2* Maximum Double Internalization-resistant (**4DIR**) diplotype subgroup (Column 6) treatment effect exceeds the Column 2 *ADRB1* Arg389Arg group by 1.34 fold (P=0.0017). The combination of the

4DIR subgroup with non-overlapping *ADRB1* Arg389Arg genotype subjects (Column 7) creates a subgroup that is 33% larger than the Column 2 index pharmacogenetic group (N=441 vs. 331), with a 1.03 fold marginally higher (P=0.064) treatment effect on the paired endpoints analysis. Finally, the requirement that both the *ADRB1* Arg389Ser49 homozygous diplotype AND internalization-resistant *ADRB2* diplotypes be present (Column 8, 10% of the total cohort, the *ADRB1* Arg389 Ser49 homozygous diplotype subset of 4DIR) creates an increase in treatment effect of 1.52 fold >Column 2 (P=0.004), and 1.92 fold >Column1 (P=0.001). Analogous data for the All LVEF cohort are similar (**Table S16** and **Figure S14**),

ERK1/2 Phosphorylation in Human Isolated Right Ventricular Trabeculae

In order to confirm that bucindolol acts as a biased ligand in the human heart and is capable of activating a putative cardioprotective pathway, ERK1/2 phosphorylation (pERK1/2) was assessed in preparations of right ventricular (RV) trabeculae isolated from 6 human explanted failing hearts, 5 of which had ≥3 copies of {*ADRB1* + *ADRB2*} (**Table S17**). After a 5- (N=1) or 10-minute (N=5) tissue bath incubation, bucindolol (P=0.0027 vs. Vehicle) but not metoprolol (P=0.38) is associated with an increase in pERK1/2 compared to vehicle (**Figures S15 and S16, Table S17**). Isoproterenol's pERK1/2/total ERK is similar to bucindolol's (respectively 1.36±0.36 vs. 1.40±0.27, P=0.73) (**Table S17**) but due to greater variability (**Figure S16**) it is not statistically significant (P=0.104 vs. Vehicle). At 60 minutes bucindolol uniquely is decreased compared to values at 5/10 minutes, 0.87±0.55 vs. 1.40±0.27, P=0.037 for interaction with time.

DISCUSSION

For same-allele nonsynonymous SNPs it is the encoded protein haplotype encompassing each polymorphic locus that has the potential to modify biologic effects.[36-38,41] This has been previously shown for *ADRB2* haplotypes expressed in COS-7 cells, where mRNA, protein and pharmacologic phenotype are haplotype encoded.[42] The *ADRB1* 389/49 haplotype would be expected to encode a higher

function β_1-AR that easily internalizes on agonist exposure (Arg389Gly49), a higher function receptor relatively resistant to internalization (Arg389Ser49), and a lower function receptor resistant to internalization (Gly389Ser49).[27] The 4th possibility, Gly389Gly49, would theoretically have lower function and would easily internalize, but was not found in this and most other genotyping studies,[27,43] presumably due to strong linkage disequilibrium. The β_2-AR has 2 loci that in tandem regulate internalization, with the Gln27Arg16 haplotype exhibiting a high level of agonist mediated internalization[9,23-25] and/or rapid desensitization.[22,23] Similar to *ADRB1*, only 3 *ADRB2* haplotypes are usually found in genetic studies including in the current report, with Glu27Arg16 absent. The absence of 1 of 4 possible haplotypes in each β-AR gene allows near certain maximum likelihood haplotyping from genotype data, and long-read DNA sequencing confirmed that for both *ADRB1* and *ADRB2* double heterozygote genotypes only 1 expected haplotype was present (respectively Arg389Gly49/Gly389Ser49 and Gln27Arg16/Glu27Gly16).

***ADRB1*, *ADRB2* Haplotypes in the BEST Adrenergic Receptor Polymorphism Substudy.**

The data from the BEST Adrenergic Receptor Polymorphism substudy indicated that placebo treatment results in reduced clinical event rates in patients who have *ADRB1* and *ADRB2* haplotypes encoding internalizing receptor variants. In a HF patient treated with placebo internalization would presumably occur on exposure to increased NE levels, present in both clinical trial populations. In the BEST substudy, across 7 clinical endpoints placebo-treated subjects with ≥3DI internalizing haplotypes had lower clinical event rates with ORs <1.0 compared to counterpart haplotypes, whereas patients with internalization-resistant (≥3DIR) haplotypes exhibited higher event rates with ORs >1.0. These results are consistent with data from the MAP-MI study, with those previous observations extended to the combination of {*ADRB1* + *ADRB2*} internalizing haplotypes.

In contrast, subjects in the bucindolol group exhibited more uniform effects across internalization tiers, with event rates similar to placebo in internalizing haplotypes and no statistically significant event

rate differences in ORs between haplotype tiers. As a result, on unadjusted analyses bucindolol vs. placebo treatment effect event rate ORs were lower in subjects with internalization-resistant (≥3DIR) haplotypes and trended lower in Incompletely Internalizing (2I) subjects. Structural equation modeling of 7 clinical endpoint events progressing from 0 to 4 internalization-resistant haplotypes confirmed the effects suggested by the unadjusted analyses, as placebo-treated subjects exhibited an increase in event rate slopes and bucindolol treatment was associated with no changes. These differences led to bucindolol vs. placebo treatment effects consistently favoring internalization-resistant haplotypes. The event rate OR data were further corroborated by time to clinical event analyses, where placebo treatment resulted in a reduction in HzRs in subjects with internalizing (≥2DI) compared to internalization-resistant (≥2IR) haplotypes. In contrast, for bucindolol treatment there was no difference between subjects with ≥2DI vs. ≥2IR haplotypes, with HzRs similar to placebo in the ≥2DI haplotype group. That is, when there is at least 1 internalizing haplotype for *ADRB1* AND *ADRB2*, placebo in the presence of a β-agonist (NE) has a favorable effect approximately equivalent to bucindolol. With bucindolol treatment the effects of NE on receptor internalization in subjects with ≥2DI, internalizing haplotypes would presumably be blocked, with biased ligand effects leading to internalization/and or blockade of any adverse effects mediated through canonical cell surface signaling. In contrast, in subjects with ≥2IR, internalization-resistant haplotypes, bucindolol exhibited efficacy in excess of placebo with statistically significant treatment effects ranging from 24% to 36% for time to effect analyses regardless of race. The therapeutic preference of bucindolol for internalization-resistant haplotypes was underscored by results in 4DIR subjects, who exhibited treatment effects from 51% to 83%. Therefore, compared to placebo, the biased ligand β-blocker bucindolol was associated with a more favorable treatment effect in subjects with internalization-resistant haplotypes, which constituted approximately 70% of the BEST substudy All LVEF cohort.

***ADRB1*, *ADRB2* Haplotypes in the GENETIC-AF Trial≥**

The limited sample size of the GENETIC-AF DNA substudy was nevertheless sufficient to detect β-AR haplotype effects on NT-proBNP and NE. Both NT-proBNP and NE plasma levels were reduced by bucindolol compared to metoprolol, similar to results in the entire cohort.[34,44] In the substudy the reductions in both biomarkers occurred only in the Bucindolol Arm in subjects with 4DIR or ≥2IR internalization-resistant haplotypes. In contrast, metoprolol succinate was not associated with a reduction in NT-proBNP or NE in subjects with internalization-resistant haplotypes. Thus relative to internalization category haplotypes the effect of the nonbiased antagonist metoprolol was different from bucindolol, and from placebo in the BEST substudy where clinical events were reduced in ≥2DI subjects. This suggests that in subjects with ≥2DI, internalizing haplotypes metoprolol blocked the beneficial, receptor internalizing effects of NE, but did not produce any favorable effects on its own. This could be because metoprolol is a nonbiased ligand, or because as β_1-AR selective antagonist β_2-AR adverse canonical signaling was unaffected.

Data comparing types of pre-randomization β-blocker treatment were consistent with a delay in bucindolol's favorable effects on NT-ProBNP in subjects who had received carvedilol, in contrast to an immediate effect in patients treated with other β-blockers. In addition, for patients treated with carvedilol pre-randomization the NT-proBNP level after 24 weeks of bucindolol treatment was statistically significantly lower than the baseline value drawn just prior to discontinuation of carvedilol. For metoprolol arm subjects with ≥2IR haplotypes, NT-proBNP levels rose after discontinuing carvedilol, consistent with pre-randomization carvedilol but not other β-blockers having inhibited the production of this biomarker. These data suggest that the biased ligand carvedilol reduced NT-ProBNP only in subjects with internalization-resistant haplotypes, but perhaps to a lesser extent than that for bucindolol. For effects on NE, also confined to bucindolol in subjects with ≥2IR haplotypes, patients with prior carvedilol treatment exhibited immediate effects, and there was no increase in NE over time

in metoprolol arm ≥2IR patients. These findings are consistent with carvedilol having no effect on systemic NE levels.[45]

Haplotype Data Indicate that Both *ADRB1* and *ADRB2* Internalizing Variants Affect Heart Failure Clinical Events and Bucindolol Treatment Effects.

Human cardiac myocytes contain β_2-ARs that are coupled to positive inotropic effects via the canonical cAMP/PKA pathway,[1] and to ERK1/2 signaling following internalization.[10] When overexpressed in mouse hearts human β_2-ARs mediate histopathological effects,[2,46] and in failing human ventricles the proportion of β_2-ARs/Total β-ARs is increased, from 20-25% to 35-40%.[1] However, the numerically dominant β_1-AR signaling pathway is more biologically adverse, and in clinical trials mortality reduction outcomes are similar for β_1-AR selective blocking agents and the nonselective, biased ligand β-blocker carvedilol.[1] Despite these observations, in the current study with placebo treatment *ADRB2* internalizing haplotypes were associated with improved clinical outcomes, and internalization-resistant haplotypes conferred improved bucindolol treatment effects. Furthermore, haplotype copy number dose-response indicated that *ADRB2* effects were equivalent to those for *ADRB1* haplotypes. These data support that in the human heart myocardial β_2-ARs are operational in the natural history of adrenergically-mediated pathologic ventricular remodeling, and that their pharmacologic manipulation can have therapeutic consequences. Moreover, for clinical endpoints the combination of *ADRB1* and *ADRB2* internalization-resistant haplotypes was additive, as might be expected based on the known differences in their encoded receptor signaling pathways.[1]

Effects of Race

As it does for the *ADRB1* Arg389Gly polymorphism,[39] race also affected β-AR internalization variants, and was the only baseline characteristic in the BEST adrenergic receptor polymorphism substudy that consistently varied by diplotype. Blacks compared to non-Blacks had higher frequencies

of internalizing and lower frequencies of internalization-resistant haplotypes, which suggests that in the absence of other confounding variables placebo treatment (or presumably no treatment) would favor Blacks based on the beneficial impact of a greater frequency of internalizing *ADRB1* and *ADRB2* haplotypes. In contrast, some of bucindolol's efficacy enhancement is dependent on the presence of internalization-resistant haplotype encoded receptors, for which non-Blacks had a slight advantage. However, as shown in the current and a previous genotype study,[39] within the same haplotypes Blacks have therapeutic responses to bucindolol that are equivalent to those in non-Blacks. These observations underscore the value of pharmacogenetic targeting in predicting drug response, which can override any contribution by baseline characteristics such as race or other potentially confounding variables.

Biased Ligand Properties of Bucindolol

A biased β-adrenergic receptor ligand can be defined as a compound that can signal through both G-protein dependent and independent pathways,[47,48] favoring one or the other in certain contexts.[47] Cardiac myocyte surface membrane β_1- or β_2-ARs typically signal through the G-protein-cAMP/PKA or CaMKII pathway,[1] and internalized receptors[8,10,12,30-32] through EGFR/ERK1/2. As it applies to bucindolol or the structurally similar compound carvedilol,[48] in systems that are hypersensitive for the detection of G protein mediated adenylate cyclase stimulation/cAMP generation both compounds exhibit weak β-agonist activity, but also can activate MAP kinase ERK1/2 independent of G-proteins[14] qualifying them as biased ligands. For both compounds the β-agonist activity is insufficient for activation of the β_1- or β_2-AR pathway in the human heart either in vitro[29,49,50] or in vivo;[51,52] data from the current study indicate that in failing human hearts bucindolol is capable of activating ERK1/2 signaling, further qualifying it as a biased ligand.

A comparison of factors influencing the biased ligand properties of bucindolol and carvedilol includes: similar ligand binding characteristics that differ from other β-AR antagonists when co-crystallized with the avian β_1-AR;[48] higher potency of bucindolol for ERK1/2 activation;[14] similar

guanine nucleotide modulatable binding (a characteristic of agonists) in human β_1- and β_2-ARs;[49,50] and for bucindolol but not carvedilol, following 24 hours of incubation downregulation of β_1- and β_2-ARs with no reduction in cognate mRNA[53] (evidence of internalization leading to receptor degradation from trafficking to lysosomes.[54,55]). These latter experiments were performed in both cultured avian cardiac myocytes (primarily β_1-ARs) and hamster β_2-AR containing smooth muscle cells that express internalization-resistant β-AR haplotypes.[56,57] In addition, bucindolol's or carvedilol's ERK1/2 activation can be blocked by endocytosis/internalization inhibitors.[58]

In the current study the increase in ERK1/2 phosphorylation in response to bucindolol occurred rapidly (after a 10 minute incubation) as noted by others for isoproterenol[12] and nebivolol,[17] and converted to dephosphorylation by 60 minutes. The degree of early activation was quantitatively similar to the statistically nonsignificant change for isoproterenol, and the nonbiased β-blocker metoprolol did not activate ERK1/2 signaling. Five of the 6 isolated RV trabeculae preparations were from failing hearts with a majority of internalization-resistant (*ADRB1* + *ADRB2*) haplotypes (four ≥3DIR and one 4DIR). These findings support the possibility that the favorable effects of bucindolol in internalization-resistant receptors could have been due to "cardioprotective" signaling mediated either by biased ligand-induced receptor internalization[15-17] or ERK1/2 signaling independent of internalization.[59,60] That a biased ligand β-blocker can internalize relatively resistant β-AR haplotypes and activate ERK1/2 signaling has been previously established with carvedilol,[16] in β_1-ARs expressed from the original human β_1-AR cDNA that is Gly389Ser49.[61]

Possible Interaction of Carvedilol with Internalization Characteristics of β-Adrenergic Receptor Haplotypes

Carvedilol's interaction with β-AR haplotypes in clinical HF settings has not been previously investigated. Despite their similarities bucindolol and carvedilol have somewhat different properties, including moderate sympatholysis with bucindolol but not by carvedilol[1,45] that likely contributes to the

former's enhanced effectiveness in HF patients homozygous for *ADRB1* Arg389.[1,29,62,63] Unlike bucindolol, carvedilol has not exhibited selective enhancement of transplant-free survival in subjects with *ADRB1* Arg389Arg[64,65] genotypes. Bucindolol is also a more potent β_2-AR antagonist than carvedilol, by approximately 5-8 fold.[50] In the current study, GENETIC-AF baseline NT-proBNP data from patients receiving pre-randomization carvedilol vs. other β-blockers produced a signal for a differential carvedilol effect in subjects with ≥2IR vs. ≥2DI haplotypes. In carvedilol treated subjects pre-randomization bucindolol treatment was associated with a slowly progressive reduction in NT-proBNP that did not achieve statistical significance until 24 weeks, suggesting a washout of a carvedilol effect on lowering NT-proBNP since in "Not Carvedilol" subjects the bucindolol reduction in NT-proBNP was statistically significant at 4 weeks. In the metoprolol treatment arm the NT-proBNP value at 24 weeks in ≥2IR, carvedilol pre-treated subjects was higher than in patients given pre-randomization β-blockers other than carvedilol, again suggesting washout of a carvedilol reduction in NT-proBNP that was confined to subjects with internalization-resistant haplotypes. These data suggest that the biased ligand carvedilol has an effect qualitatively similar to bucindolol, which may have been quantitatively less since the 24 week value in ≥2IR bucindolol subjects was lower than the baseline value that reflected pre-randomization carvedilol treatment.

Haplotype Targeting Expands the Pharmacogenetic Heart Failure or Atrial Fibrillation Prevention Potential of Bucindolol

In BEST substudy subjects with LVEFs ≥0.20 the enhanced treatment effects of bucindolol in subjects with both *ADRB1* and *ADRB2* Maximum Double Internalization-resistant (4DIR) diplotypes (a 25% subgroup) resulted in a 1.34 fold increase in treatment effects compared to the *ADRB1* Arg389Arg index population, and 1.68 fold increase compared to the All-Genotypes cohort. If *ADRB1* Arg389Ser49 homozygous diplotypes AND 4DIR diplotypes were considered (a ≈10% subgroup) the treatment effect enhancement compared to the index *ADRB1* Arg389Arg group was by 1.52 fold in the LVEF ≥0.20

cohort and by 1.40 fold in the All-LVEFs cohort, with respective increases vs. the All-Genotypes cohort of 1.92 and 2.06 fold. Thus, efficacy enhancement through targeting internalization-resistant *ADRB1* and *ADRB2* haplotypes exceeds that for *ADRB1* Arg389Arg, and when combined with this genotype using AND logic yields an approximate doubling in effectiveness.

When the *ADRB1* AND *ADRB2* ≥4DIR subgroup was combined with *ADRB1* Arg389Arg subjects by OR logic the result was a 60-62% subgroup that was essentially identical to *ADRB1* Arg389Arg for treatment effects, in both LVEF cohorts. As a result, in the BEST pharmacogenomics substudy the addition of internalization-resistant *ADRB1* and *ADRB2* haplotypes ("haplotype targeting") to the current *ADRB1* Arg389Arg targeting resulted in a larger population eligible for benefit, increasing from 45-47% to 60-62% of the all-genotype parent population. Since the BEST pharmacogenetic substudy was enriched in Blacks, who have a lower frequency of both *ADRB1* Arg389 and internalization-resistant *ADRB1* and *ADRB2* haplotypes, the race-adjusted eligibility for therapeutic enhancement in the entire U.S. population would increase from 49% to 65%. Thus, by using the *ADRB1* Arg389Arg OR (*ADRB1* AND *ADRB2* Internalization-resistant algorithm the population eligible for treatment enhancement can be increased by 33%.

Heart Failure Natural History Implications

The effects in the placebo-treated group could have implications for HF natural history, which suggest that patients with ≥2 (ADRB1 + ADRB2) internalizing haplotypes have a more favorable prognosis, may not respond any better than placebo to a biased ligand β-blocker and could have worse outcomes when treated with a non-biased β-blocker.

Potential Limitations

These data were generated in 2 previously conducted clinical trials, one of which[35] was from an era when HFrEF therapy did not include two (sacubitril-valsartan and SGLT2 inhibitors) of the current "Four Pillars"[66] of HF drug treatment, and the other[34] was prior to the regulatory approval and

therapeutic implementation of SGLT2is. Although the tested hypothesis was generated from observations made in a more recent study,[27] further clinical outcomes testing of the β-AR haplotype internalization hypothesis is warranted in contemporary HF populations.

In addition to the biased ligand/receptor internalization/cardioprotective signaling hypothesis there are other possible explanations for the differential effects of apparent receptor internalization treatment associated clinical events. These include non-EGFR/ERK1/2 subcellular signal trafficking[67] of encoded internalized haplotypes, and internalization-based exclusion of cell surface β-ARs from adverse canonical signaling. In the latter paradigm the benefit of internalized, desensitized β-ARs in the presence of placebo is simply to attenuate the adverse effects of cell surface canonical signaling,[16,68] while bucindolol as a high affinity β_1-, β_2-AR antagonist[1,49,50] exerts a greater therapeutic effect when receptors are non-internalized. These possible mechanistic explanations will need to be further investigated in cardiac myocyte model systems expressing human β-AR haplotypes.

Conclusions

In HFrEF and HFmrEF patients, polymorphic loci in the intronless *ADRB1* and *ADRB2* genes encoding receptor haplotypes that regulate internalization affect HF and AF clinical events as well as biomarker behavior, in both placebo- and bucindolol-treated subjects. Including *ADRB1* and *ADRB2* internalization-resistant haplotypes in bucindolol's pharmacogenetic targeting results in efficacy enhancement similar to that produced by the *ADRB1* Arg389Arg genotype, and restricting the *ADRB1*contribution to Arg389 in a internalization-resistant diplotype combination produces an additive effect as would be expected by polymorphisms affecting different mechanisms. Haplotype pharmacogenetic targeting is feasible in HF, and can identify populations at differential risk for serious outcomes as well as candidates for increased therapeutic effectiveness.

METHODS

Sex as a Biological Variable

Subjects of either sex (self-identified and recorded on case report forms) were enrolled in the 2 clinical trials[34,35] as well as in their DNA substudies[29,69] that were investigated in the current report. The protocol for isolated human heart ERK1/2 phosphorylation (RV trabeculae from failing hearts explanted at cardiac transplantation) included either sex, but by chance all 6 procured hearts were from males. The structural equation model as well as time to event curves included an adjustment for sex.

Race as Modifier of Polymorphism and Haplotype Frequencies.

The race/ethnicity case report form classifications in both clinical trials were "White, Black, Hispanic, Asian/Pacific Islander, American Indian/Alaskan, Other" determined by self-identification. In the current as well as previous reports,[35] Blacks were assigned one racial category, and all other races were classified as non-Blacks.

Clinical Trial DNA Substudies

Beta-blocker Evaluation of Survival Trial (BEST), NCT00000560) Pharmacogenomic Substudy

The "Pharmacogenomics of β-Adrenergic Receptor Polymorphisms and Response to β-blockers in Heart Failure" substudy ("BEST Pharmacogenomics Substudy"[29] of the Beta-Blocker Evaluation of survival Trial (BEST)[35] (Stephen Liggett, PI, William Abraham, Co-PI) was designed to investigate "whether polymorphisms of the β_1- and β_2-adrenergic receptors predict responsiveness to bucindolol in heart failure", and "whether these polymorphisms can account for the racial differences in response to bucindolol which have been observed in BEST". The 1040 patient substudy[29] and its parent trial[35] have been previously described, including the BEST trial protocol details.[70] The primary endpoint of the parent trial was time to all-cause mortality (ACM), with secondary endpoints of time to: 1) ACM or cardiac transplantation (ACM/Tx), and heart failure hospitalization (HFH). At FDA request after completion of the trial time to cardiovascular hospitalization (CVH) was also measured,[71] and the composite of time to CVM/HFH, now the preferred primary endpoint in Phase 3 trials, has also been

analyzed and reported.[72] BEST randomized an advanced HFrEF (Heart Failure with reduced LV Ejection Fraction) population (NYHA Class III and IV, with LVEFs ≤0.35). The trial was sponsored by the NHLBI, and with the exception of 2 Canadian centers was conducted in the U.S, with the study population purposely enriched for Blacks (22% in the substudy[29,39]). In the current study results were analyzed by race as well as within 2 LVEF cohorts, one with all subjects ("All-LVEF") and the other with an LVEF ≥0.20. The latter cohort was investigated because the patients in it were more stable and less likely to have confounding clinical characteristics.

GENETIC-AF (NCT01970501) DNA Substudy

GENETIC-AF was a 267 subject Phase 2 trial in HFrEF and HFmrEF (HF with mildly reduced LV Ejection Fraction, defined as LVEFs between 0.40 and 0.49) patients with a history of persistent or paroxysmal AF, randomized to bucindolol or metoprolol succinate for AF prevention after spontaneous or electrical cardioversion attainment of sinus rhythm.[34] The protocol details[69] including a consort diagram[34] have been previously published. The patient population consisted of *ADRB1* Arg389Arg genotype HF patients who had an episode of symptomatic atrial fibrillation (AF) in the past 6 months, and NYHA Class I-III HF with LVEFs <0.50 at screening. The primary endpoint of GENETIC-AF was time to atrial fibrillation, or atrial flutter, or ACM (AF/AFL/ACM), and norepinephrine (NE) and NT-proBNP were tertiary endpoints.[34]

Isolated Human Heart Studies

Tissue Bath Preparations

Explanted failing hearts from end stage heart failure patients with nonischemic or ischemic cardiomyopathies were obtained at the time of cardiac transplantation and immediately transported to the laboratory in iced Tyrode's solution. Right ventricular trabeculae (N=10-14) of uniform size (1-2 x 6-8 mm) were mounted in tissue baths in Tyrode's solution at 37º and field stimulated to contract at 60 bpm, as previously described.[29] Following a 1 hour equilibration period 1-2 trabeculae/group were

incubated with vehicle, isoproterenol (1umol/L), bucindolol HCL(1umol/L) or metoprolol tartrate (10 umol/L) for either 5, 10 or 60 minutes. At the end of its incubation period each trabeculum was removed from the bath, flash frozen in liquid nitrogen and stored at -80°C.

pERK1/2 Immunoblotting

Frozen trabeculae (25-35 mg) were homogenized in 25 volumes of a homogenization buffer cocktail (8M Urea, 2.5M thio-Urea, 4% CHAPS, 2mM EDTA, 0.01M dithiothreitol, 1% Protease Inhibitor Cocktail (Sigma P-8340) and 1% ReadyPrep TBP Reducing Agent (BioRad 1632101)) in glass mortar and pestle tissue grinders on ice. Supernatant fractions were saved after a 13,600xg centrifugation, aliquoted and frozen at -80°C. Total protein content of the supernatants was determined by a Bradford assay (Pierce Detergent Compatible 1863028).

Immunoblots were performed on 5 micrograms of protein per sample by SDS-PAGE separation in 10% polyacrylamide gels (BioRad, Mini PROTEAN TGX 4561036), then transferred to 0.2 µm PVDF membranes (BioRad, ImmunBlot 16201777). Primary antibodies for ERK (Cell Signaling 9102), pERK (Cell Signaling 9101) and GAPDH (Santa Cruz 32233) were applied sequentially to the blots with the subsequent appropriate HRP-linked secondary antibody following (Sigma A2304 and A9169). Chemiluminescence was initiated (ThermoScientific SuperSignal West Pico-plus 34580) and captured by exposure to film that was then scanned and imaged by software package (ImageJ, NIH, imageJ.org). Chemical stripping of antibodies from the blot was performed between each primary antibody detection, before application of the next set of antibodies. pERK1/2 density was normalized to its respective unphosphorylated band, and compared to vehicle control at each incubation timepoint.

Genotyping and Haplotyping.

BEST Pharmacogenomics Substudy genotyping for *ADRB1* Arg389Gly, *ADRB1* Ser49Gly, *ADRB2* Gln27Glu, and *ADRB2* Gly16Arg was conducted by Restriction Fragment Length Polymorphism (RFLP) conducted in DNA extracted from whole blood as previously described,[29,73] with results

subsequently confirmed by DNA sequencing. For GENETIC-AF subjects the *ADRB1* Arg389Arg genotype necessary for trial enrollment was determined by TaqMan® SNP genotyping as previously described,[34] while the *ADRB1* Ser49Gly genotype and *ADRB2* genotypes were measured by sequencing SNP flanking-primer PCR amplicons using DNA extracted from the *ADRB1* Arg389Gly genotyping. Haplotyping in both substudies was via an expectation-maximization (EM) algorithm for maximum likelihood estimates, using the "Haplo.stats" package available in R.[27,74] Linkage disequilibrium was tested using the R based "genetics" package (https://CRAN.R-project.org/package=genetics). Haplotypes for pairwise SNPs are only ambiguous in the double heterozygote case; thus, for both *ADRB1* and *ADRB2* 20 double genotype heterozygote DNA samples were subjected to long-read sequencing[75] that confirmed the likelihood reads of missingness of 1 haplotype from each gene (*ADRB1* Gly389Gly49 and *ADRB2* Glu27Arg16).

Quantitation and Statistical Analysis

Clinical Trial Substudy Data

The overall aim of the statistical analysis was to compare clinical event and biomarker outcomes in HF subjects with more vs. fewer internalizing β-adrenergic receptor (β-AR) haplotypes, across 2 clinical trials where haplotyping was performed and which had extensive outcomes databases. We thus designed a statistical approach to be consistent with each trial's original statistical analysis plan, but would also address the studies primary hypothesis that β-AR haplotypes with different internalization potential affect HF outcomes. Because of variations in cohort sample sizes internalization subdivision definitions varied slightly between analyses (described in detail in the second paragraph of **Supplemental Material**, **Conventions and Presentation Formats** and summarized in **Table S2**) but always included a comparison that encompassed internalizing vs. internalization-resistant (*ADRB1* + *ADRB2*) haplotypes.

The greater sample size of the BEST Pharmacogenomics Substudy allowed more gradation in estimation of dose-response effects of haplotype internalization (i.e., sufficient sample size for analyses

using three mutually-exclusive tiers and two separate treatment arms), whereas the GENETIC-AF DNA substudy, limited in sample size and restricted in *ADRB1* genotype to Arg389Arg, maintained the directionality of this classification by confining the analysis to two mutually-exclusive tiers that were also analyzed in the BEST cohort, in each of two treatment arms that included an active comparator.

Genotype and Haplotype Analyses

The genotype-level analyses are inherently confounded by effects related to other loci in linkage disequilibrium with the polymorphism of interest. This can be reconciled by analysis at the haplotype level, where 3 haplotypes exist for both *ADRB1* (Arg389Gly49, Arg389Ser49, Gly389Ser49) and *ADRB2* (Gln27Arg16, Gln27Gly16, Glu27Gly16), which manifest independently at the genome (different chromosomes) or statistical level (no detectable linkage disequilibrium and satisfying Hardy-Weinberg equilibrium). A standard Bonferroni adjustment for internalizing vs. internalization-resistant haplotypes for both *ADRB1* and *ADRB2* would therefore yield $\alpha = .025$ for an endpoint analysis, which was considered the adjusted α-level.

Clinical Endpoints

The endpoints prospectively chosen for analysis in the current study included the primary cardiovascular endpoints for both the BEST Pharmacogenomic and GENETIC-AF DNA substudies (ACM/Tx[29] and AF/AFL/ACM,[34] respectively), the primary endpoint of the BEST parent trial[35] (ACM) that was a secondary endpoint in its substudy, 2 secondary endpoints from the BEST parent trial (CVM, HFH),[70] 2 composite endpoints from these secondaries (CVM/HFH and ACM/HFH), and 1 post hoc endpoint (CVH) requested by the FDA.[71]

Forest Plots

Forest plots of clinical event odds ratios (ORs) were used to perform a group-level analysis of events within endpoints in patients with internalizing vs. internalization-resistant haplotypes (Figures 1-3, S1-S3). For graphical efficiency, the ACM/HFH endpoint was not included. Combined {*ADRB1* and

ADRB2} haplotypes were rank-ordered into 3 mutually exclusive tiers by haplotype internalization potential, progressing from internalizing to internalization-resistant potential. Only first events were assessed, in an unadjusted analysis in each tier's internalizing vs. all other haplotypes. The analyses were performed by treatment group and on the treatment effects of bucindolol vs. placebo, using intention to treat data. For the *ADRB1*/*ADRB2* haplotype titration forest plots (**Figures S4-S9**), constructed for pattern recognition and consistency between clinical endpoints, only the individual comparison OR 95% C.I.s and P values were calculated.

Structural Equation Modeling

The second evaluation of clinical events in patients with internalizing vs. internalization-resistant haplotypes was a subject-level analysis with covariate adjustment. These analyses were performed by treatment group, and on the treatment effects in the bucindolol vs. placebo group, using intention to treat data.

The structural equation model ("SEM") for binary outcomes (representing events from each endpoint) used the WLSMV estimator (diagonally-weighted least squares with a full mean- and variance-adjusted weight matrix for robust estimation of standard errors and chi-square based fit statistics). The readout is event likelihood for each of the seven candidate endpoints simultaneously, regressing binary outcomes onto internalization (0-4 copies of internalization-resistant haplotypes), treatment arm, the interaction of treatment arm and internalization (treatment effect), and the covariates. Inputted covariates are LVEF, Coronary Artery Disease, Sex, Race, Volume Overload, NYHA Class, AF at Baseline, DNA Lag (time between randomization and blood draw for DNA extraction), duration since HF diagnosis, duration of event free survival, age, baseline systolic blood pressure, and baseline heart rate. All these covariates have been used for stratification in the 2 clinical trials or have been shown to relate to the probability of occurrence of the primary endpoints.[34,35]

Time to First Event Analyses

For time to event (Kaplan-Meier) curves all analyses used unadjusted methodologies, as adjustments, particularly in small sample sizes, may yield misleading results. However, for sensitivity purposes we also performed analyses adjusted for randomization stratifiers and other covariates, which were not different from the unadjusted versions and are archived in the GitHub site.

Biomarker Data from the GENETIC-AF DNA Substudy

In the GENETIC-AF DNA substudy cohort the SAP[34] defined analysis for the tertiary endpoints of NT-proBNP or NE was a change from baseline values using nonparametric methods, since in previous studies these were known to be non-normally distributed. These analyses were performed on the trial's efficacy cohort (N=256), defined as receiving blinded study medication or having it stopped within 2 weeks of biomarker collection.[76]

Statistical Test Details

Time to first event Hazard Ratios (HzR) were generated by unadjusted Cox proportional hazards models, with first clinical event Odds Ratios (ORs) obtained from logistic regression models. Bucindolol treatment effects based on event rates were calculated by (Bucindolol Event Odds)/(Placebo Event Odds). Confidence intervals for linkage disequilibrium coefficients were calculated using 10,000 nonparametric bootstrapped estimates. Treatment effects between bucindolol vs. control (placebo or metoprolol succinate) were calculated from HzRs as: % treatment effect = ((1-HzR) x 100). Normality was determined by the Anderson Darling test. For normally distributed data assessing one clinical endpoint t-tests were used, and for >1 endpoint one-way ANOVA with a Holm-Sidak's test was employed. Analysis of ERK1/2 phosphorylation was by a one-way ANOVA mixed model with repeat measures and a Holm-Sidak multiple comparison test. For non-normally distributed data Wilcoxon or Friedman's/Kruskal-Wallis tests with a Dunn's multiplicity adjustment were employed.

Study Approval

The BEST trial and its pharmacogenomics substudy were approved by ethical committees at the NHLBI, Department of Veterans affairs (Palo Alto VA, location of the statistical analysis center), the DNA Oversight Committee and each investigational site. The GENETIC-AF study and its DNA substudy were approved at each investigational site. Participants in each clinical trial signed written informed consent for both the parent trial and separately for voluntary DNA sampling that could be used for genetic or other analyses with de-identification of individual subjects.

Data Availability

Outputs and code for structural equation modeling and haplotyping data are available on GitHub https://github.com/CUAMC-SoM-Cardiology/M_Bristow-Lab

Group level data not included in the manuscript are available on request. De-identified subject level data for use in a research context will be available on request.

Acknowledgements
Funding sources: This work was supported by National Heart, Lung, and Blood Institute (NHLBI) Grants HL052318, HL48013, HL071609, and HL077101. Additional support is from Genvara Biopharma, Westminster, CO. DNA samples from the BEST trial were provided by the BEST DNA Bank, co-sponsored by the NHLBI and the Department of Veterans Affairs Cooperative Studies. DNA Samples for the GENETIC-AF trial were provided by ARCA Biopharma (Westminster, CO), the trial's sponsor. We thank Rachel Rosenberg for manuscript and submission handling.

Author contributions
Conceptualization, M.R.B., I.A.C., S.B.L.; Methodology, I.A.C., M.R.B., D.S., W.A.M., E.R.J., L.A.W., A.D.K., A.V.A., S.B.L., D.K.; Software, I.A.C.; Validation, M.R.B., I.A.C., W.A.M., D.S.; Formal Analysis, I.A.C., M.R.B., D.S., W.A.M., L.A.W.; A.D.K. Investigation, S.B.L., M.R.B., I.A.C., D.S., E.R.J., W.A.M., L.A.W., D.K., A.D.K.; Resources, M.R.B., S.B.L., I.A.C., A.V.A., T.A.M; Data Curation, I.A.C, M.R.B., D.S.; Writing− Original Draft, M.R.B., I.A.C., D.S., W.A.M.; Writing – Review & Editing, M.R.B., I.A.C., S.B.L., T.A.M.,L.A.W.; Visualization, I.A.C. E.R.J., M.R.B., W.A.M; Supervision, M.R.B., S.B.L., T.A.M, D.S, A.V.A.; Project Administration, M.R.B., S.B.L.; Funding Acquisition, M.R.B., S.B.L.

REFERENCES

1. Bristow MR, et al. Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. *Circ Res.* 2011;109(10):1176-1194.

2. Liggett SB, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. *Circulation*.2000;101(14):1707-1714.
3. Tatman PD, et al. An extensive β1-adrenergic receptor gene signaling network regulates molecular remodeling in dilated cardiomyopathies. *JCI Insight*. 2023;8 (16):e169720.
4. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. *Circulation*. 1996;94 (9):2285-2296.
5. Arora R. Recent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system. *Circ Arrhythm Electrophysiol*. 2012;5(4):850-859.
6. Noma T, et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. *J Clin Invest*. 2007;117(9):2445-2458.
7. Rapacciuolo A, et al. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. *J Biol Chem*. 2003;27837):35403-35411.
8. Tilley DG, et al. Beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. *J Biol Chem*. 2009;284(30),20375-20386.
9. von Zastrow M, Kobilka BK. Ligand-regulated internalization and recycling of human beta 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors. *J Biol Chem*. 1992;267(5):3530-3538.
10. Daaka Y, et al. Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. *J Biol Chem*. 1998;273 (2):685-688.
11. Chen H, et al. β2-Adrenergic receptor-induced transactivation of epidermal growth factor receptor and platelet-derived growth factor receptor via Src kinase promotes rat cardiomyocyte survival. *Cell Biol Int*. 2012;36(3):237-244.

12. Grisanti LA, et al. β-Adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1/2 and Akt. *J Mol Cell Cardiol*. 2014;72:39-51.

13. Han SO, et al. MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound β(2)-adrenergic receptors. *J Cell Biol*. 2012;199(5):817-830.

14. Galandrin S, Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. *Mol Pharmacol*. 2006;70(5):1575-1584.

15. Wisler JW, et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. *Proc Natl Acad Sci U S A.* 2007;104(42):16657-16662.

16. Kim IM, et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. *Proc Natl Acad Sci* 2008;105(38):14555-14560.

17. Erickson CE, et al. The β-blocker Nebivolol is a GRK/β-arrestin biased agonist. PLoS One. 2013;8(8): *e71980.*

18. Levin MC, et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. *J Biol Chem*. 2002; 277(34): 30429-30435.

19. Rathz DA, et al. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. *J Cardiovasc Pharmacol*. 2002;39(2):155-160.

20. Sandilands A, et al. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. *Pharmacogenetics*. 2004;14(6):343-349.

21. Zhang F, Steinberg SF. S49G and R389G polymorphisms of the β_1-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways. *Physiol Genomics*. 2013;45(23):1186-1192. https://doi: 10.1152/physiolgenomics.00087.2013.

22. Dishy V, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. *N Engl J Med*. 2001;345(14):1030-1035.

23. January B, et al. Beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. *J Biol Chem*. 1997;272 (38):23871-23879.

24. Green SA, et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. *Biochemistry*. 1994;33(32):9414-9419.

25. Suzuki T, et al. Distinct regulation of beta 1- and beta 2-adrenergic receptors in Chinese hamster fibroblasts. *Mol Pharmacol*. 1992;41(3):542-548.

26. Kobilka BK, et al. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. *Proc Natl Acad Sci U S A*. 1987;84(1):46-50.

27. Chevalier P, et al. Impact of neuroeffector adrenergic receptor polymorphisms on incident ventricular fibrillation during acute myocardial ischemia. *J Am Heart Assoc*. 2023;12(6): e025368.

28. Mason DA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. *J Biol Chem*. 1999;274(18):12670-12674.

29. Liggett SB, et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. *Proc Natl Acad Sci U.S.A*. 2006;10330):11288-11293.

30. Eichel K, et al. β-Arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation. *Nat Cell Biol*. 2016;18(3):303-310.

31. Maudsley S, et al. The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. *J Biol Chem*. 2000;275(3):9572-9580.

32. Kwon Y, et al. Non-canonical β-adrenergic activation of ERK at endosomes. *Nature*. 2022;611(7934):173-179.

33. Börjesson M, et al. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. *Eur Heart J*. 2000;21(22):1853-1858.

34. Piccini JP, et al. Bucindolol for the maintenance of sinus rhythm in a genotype-defined HF population. *JACC Heart Fail*. 2019;7(7):586-598.

35. Eichhorn EJ, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med.* 2001;344(22):1659-1667.

36. Spooner W, et al. Haplosaurus computes protein haplotypes for use in precision drug design. *Nat Commun*. 2018;9(1):4128.

37. Judson R, et al. The predictive power of haplotypes in clinical response. *Pharmacogenomics*. 2000;1(1):15-26.

38. Drysdale CM, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. *Proc Natl Acad Sci U S A*. 2000;97(19):10483-10488.

39. Taylor MR, et al. Race, common genetic variation, and therapeutic response disparities in heart failure. *JACC Heart Fail*. 2014 2(6):561-572. https://doi: 10.1016/j.jchf.2014.06.010.

40. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. *Annu Rev Genomics Hum Genet*. 2003; 4:293-340.

41. Stephens JC, et al. Haplotype variation and linkage disequilibrium in 313 human genes. *Science*. 2001;293(5529):489-493.

42. Panebra A, et al. Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes. *PLoS One*. 2010;5(7):e11819.

43. Forleo C, et al. Beta1- and beta2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy. *J Cardiovasc Med (Hagerstown*). 2007;8(8):589-595.

44. Piccini JP, et al. Bucindolol decreases atrial fibrillation burden in patients with heart failure and the *ADRB1* Arg389Arg genotype. *Circ Arrhythm Electrophysiol*. 2021;14(8):e009591.

45. Bristow MR, et al. Second- and third-generation beta-blocking drugs in chronic heart failure. *Cardiovasc Drugs Ther*. 1997;11(Suppl 1):291-296.

46. Freeman K, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. *J Clin Invest*. 2001;107(8): 967-974.

47. Drake MT, et al. Beta-arrestin-biased agonism at the beta2-adrenergic receptor. *J Biol Chem*. 2008;283(9):5669-5676.

48. Warne T, et al. Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. *Structure*. 2012;20(5):841-849.

49. Hershberger RE, et al. Mechanism of action of bucindolol in human ventricular myocardium. *J Cardiovasc Pharmacol* 1990;15(6):959–967.

50. Yoshikawa T, et al. Cardiac adrenergic receptor effects of carvedilol. *Eur Heart J*. 1996;17(Suppl B):B8-B16.

51. Bristow MR, et al. The role of third generation β-blocking agents in chronic heart failure. *Clin Cardiol*. 1998;21(12 Suppl 1):I3-13.

52. Bristow MR, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. *Circulation*. 1994 89(4):1632-1642.

53. Asano K, et al. Bucindolol, a nonselective B1- and B2- adrenergic receptor antagonist, decreases β-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. *J Cardiovasc Pharmacol*. 2001;37(6):678-691.

54. Moore RH, et al. Agonist-induced sorting of human beta2-adrenergic receptors to lysosomes during downregulation. *J Cell Sci*. 1999;112(Pt 3):329-338.

55. Nakagawa T, Asahi M. β1-adrenergic receptor recycles via a membranous organelle, recycling endosome, by binding with sorting nexin27. *J Membr Biol* 2013;246(7):571-579.

56. Chicken *ADRB1*, human equivalent haplotype is Arg389Ser49. https://www.ncbi.nlm.nih.gov/nuccore/XM_040703024.2?report=GenBank . Accessed 3/10/2025.

57. Hamster *ADRB2*, human equivalent haplotype is Glu27Gly16. https://www.ncbi.nlm.nih.gov/nucleotide/XM_027402776.2?report=genbank&log$=nuclalign&blast_rank=1&RID=WYT2ZYU3016 . Accessed 3/10/2025.

58. Ajumobi, T. Beta-Blockers Act through clathrin-dependent internalization and EGFR transactivation to promote ERK Phosphorylation. (2014). Graduate Thesis Collection. *267*. https://digitalcommons.butler.edu/grtheses/267. Accessed 4/24/2024.

59. Galandrin S, et al. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. *Mol Pharmacol*. 2008;74(1):162-172.

60. Huang J, et al. Distinct roles for Src tyrosine kinase in beta2-adrenergic receptor signaling to MAPK and in receptor internalization. *J Biol Chem*. 2004;279(20):21637-21642.

61. Frielle T, et al. Cloning of the cDNA for the human beta 1-adrenergic receptor. *Proc Natl Acad Sci U S A*. 1987;84(22):7920-7924.

62. Aleong RG, et al. Prevention of atrial fibrillation by bucindolol is dependent on the $beta_1$389 Arg/Gly adrenergic receptor polymorphism. *JACC Heart Fail*. 2012;1(4):338-344

63. Aleong RG, et al. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. *Circ Arrhythm Electrophysiol*. 2013;6(1):137-143.

64. Sehnert AJ, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. *J Am Coll Cardiol*. 2008;52(8):644-651.

65. White HL, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. *Eur J Heart Fail*. 2003;5(4):463-468.

66. Straw S, et al. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction. Open Heart. 2021;8(1):e001585..

67. Wei W, Smrcka, AV. Subcellular beta-adrenergic receptor signaling in cardiac physiology and disease. *J Cardiovasc Pharmacol*. 2022 80(3):334-341.

68. Tan LB, et al. Beta adrenergic receptor desensitization may serve a cardioprotective role. *Cardiovasc Res*. 1992;26(6):608-614.

69. Piccini JP, et al. A genotype-directed comparative effectiveness trial of bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. *Am Heart J*. 2018;199:51-58

70. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). *Am J Cardiol.* 1995;75(17):1220–1223.

71. O'Connor CM, et al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. *PLoS One*. 2012;7(10): e44324

72. Shen L, et al. Re-examination of the BEST trial using composite outcomes, including emergency department visits. *JACC Heart Fail*. 2017;5(8):591-599.

73. Small KM, et al. Identification of adrenergic receptor polymorphisms. *Methods Enzymol*. 2002;343:459–475.

74. Sinnwell, J.P., Schaid, D.J. HAPLO.STATS: Statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous. R package version 1.8.7. https://CRAN.R-project.org/package=haplo.stats. Accessed 4/16/2024.

75. Porubsky D, et al. Fully phased human genome assembly without parental data using single-cell strand sequencing and long reads. *Nat Biotechnol*. 2021;39(3):302-308.

76. Abraham WT, et alDose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial. Heart Rhythm O2. 2021;3(1):40-49.

TABLES

Table 1. *ADRB1*, *ADRB2* diplotype frequencies (*f*) by race, BEST Adrenergic Receptor Polymorphism Substudy.

Gene	Diplotype	Black	non-Black	All Races	B/non-B Fold Difference	P value, Black vs. non-Black
		N = 205 *ADRB1*, 207 *ADRB2* (*f*)	N = 824 *ADRB1, 833 ADRB2* (*f*)	N = 1029 *ADRB1*, 1040 *ADRB2* (*f*)		
ADRB1	Arg389Ser49 Arg389Ser49	21 (0.10)	281 (0.34)	302 (0.29)	0.29	<0.0001
	Arg389Gly49 Arg389Gly49	14 (0.068)	24 (0.029)	38 (0.037)	2.34	0.012
	Gly389Ser49 Gly389Ser49	35 (0.17)	58 (0.070)	93 (0.090)	2.43	<0.0001
	Arg389Ser49 Arg389Gly49	30 (0.15)	119 0.14)	149 (0.145)	1.07	0.91
	Arg389Gly49 Gly389Ser49	40 (0.20)	61 (0.074)	101 (0.098)	2.70	<0.0001
	Arg389Ser49 Gly389Ser49	65 (0.32)	281 (0.34)	346 (0.34)	0.94	0.56
ADRB2	Gln27Gly16 Gln27Gly16	19 (0.092)	51 (0.061)	70 (0.067)	1.51	0.12
	Gln27Arg16 Gln27Arg16	41 (0.20)	137 (0.16)	178 (0.17)	1.25	0.26
	Glu27Gly16 Glu27Gly16	7 (0.034)	136 (0.16)	143 (0.14)	0.21	<0.0001
	Gln27Arg16 Gln27Gly16	77 (0.37)	133 (0.16)	210 (0.20)	2.31	<0.0001
	Gln27Arg16 Glu27Gly16	35 (0.17)	244 (0.29)	279 (0.27)	0.59	0.0002
	Gln27Gly16 Glu27Gly16	28 (0.14)	132 (0.16)	160 (0.15)	0.23	0.45
	Not Gln27Arg16 Gln27Arg16	166 0.80	696 0.84	862 0.83	0.95	0.26
	1 or 2 copies Gln27Arg16	153 (0.74)	514 (0.62)	667 (0.64)	1.19	0.0012
	No copies Gln27Arg16	54 (0.26)	319 (0.38)	373 (0.36)	0.68	0.0012

f = Diplotype frequency (Diplotype N/Total N).

FIGURES and LEGENDS



Figure 1. All LVEF cohort patients randomized to placebo in the BEST Adrenergic Receptor Polymorphism substudy, forest plot of *ADRB1* + *ADRB2* combination diplotypes arranged by the number of internalizing haplotypes (Column 1), displaying Odds Ratios (ORs, Columns 4 and 7) between event rates (Column 6) in the Column 1 diplotypes vs. all other combination diplotypes. The *ADRB1*, *ADRB2* diplotype combinations are displayed by "≥3 Double Internalizing" combinations in **Tier 1** (**≥3DI**, 1 or 2 copies of *ADRB1* Arg or Gly389Gly49 AND *ADRB2* Gln27Arg16, for a total of 3-4 copies of an internalizing haplotype); "Incompletely Internalizing" in **Tier 2** (**2I)**, 2 total copies of internalizing haplotypes, either 1 copy of *ADRB1* AND *ADRB2*, or 2 copies on one of them); and "≥3 Double Internalization-resistant" haplotype combinations in **Tier 3** (**≥3DIR,** 0-1 total copies of *ADRB1* Arg or Gly389Gly49 AND *ADRB2* Gln27Arg16, 3-4 copies of internalization-resistant haplotypes). The counterpart, comparison haplotypes used to generate ORs follow OR logic, i.e. if either the *ADRB1* or the *ADRB2* haplotype doesn't match the cognate Column 1 haplotype then the pair becomes a member of the counterpart group. Column 6 lists the event rate and [N] in the paired haplotypes in column 1, followed by the event rate and [N] in the counterpart, comparator groups. CVM=Cardiovascular Mortality; AF/AFL/ACM=Atrial fibrillation, Atrial Flutter or All-Cause Mortality; CVM/HFH=CVM or Heart Failure hospitalization; HFH=Heart Failure Hospitalization; ACM/Tx=ACM or Cardiac Transplantation; CVH=Cardiovascular Hospitalization; ACM=All-Cause Mortality. For the AF/AFL/ACM endpoint, only non-AF patients at the time of randomization are analyzed, resulting in a smaller N than for the 6 HF endpoints. For all endpoints only first events are considered. Odds Ratios (ORs) are calculated by: [(Index event rate in %) / (100 − Index event rate)] / [(Comparator event rate) / (100 − Comparator event rate)], or in Row 1 (8.3/91.7) / (18.8/81.2) = 0.39.



Figure 2. All LVEF cohort BEST substudy patients randomized to bucindolol in the BEST Adrenergic Receptor Polymorphism substudy. The forest plot is constructed as for **Figure 1**.



Figure 3. All LVEF cohort subjects, forest plot of bucindolol vs. placebo treatment effect (bucindolol event rate vs. placebo event rate) Odds Ratios (ORs) by internalizing haplotype number in the Column 1 *ADRB1* + *ADRB2* combination diplotypes. [Ns] are the number of subjects in the bucindolol and placebo groups respectively; otherwise set-up is as in Figures 1 and 2.



Figure 4. Time to first event curves in bucindolol vs. placebo treated patients with Maximum Double Internalization-resistant (**4DIR**), total of 4 internalization-resistant haplotypes), LVEF ≥0.20 cohort N=184. **A.** All-cause Mortality or Cardiac Transplantation (ACM/Tx); **B.** Heart Failure Hospitalization (HFH); **C.** Cardiovascular Mortality or Heart Failure Hospitalization (CVM/HFH); **D.** Cardiovascular Hospitalization (CVH).



Fig 5. Time to first event curves curves in Blacks or non-Blacks in the All LVEF cohort for the CVM/HFH (**A**) and CVH (**B**) time to first event endpoints, with haplotype categories of: Double Internalizing (**DI**) = ≥1 *ADRB1* AND *ADRB2* internalizing haplotypes (*ADRB1* Arg389Gly49, *ADRB2* Gln27Arg16); Double internalization-resistant (**NDI**) = all other haplotypes. The ≥2DI subpopulation is 18.4% of subjects treated with placebo.



Fig 6. GENETIC-AF study, **A.** NT-proBNP change from Baseline for subjects with ≥2 double internalizing *ADRB1* AND *ADRB2* haplotypes (**≥2DNI**) or ≥2 Internalization-resistant haplotypes (**≥2IR**) in the Bucindolol or Metoprolol Groups; **B.** Absolute levels in NT-proBNP; **C.** Change from baseline in norepinephrine; **D.** Absolute levels of norepinephrine. Baseline values, changes by diplotype and **4DIR** data are in **Tables S11-S14**.

Main Effects of Internalization Tier within Placebo Patients (Unadjusted, All LVEF Subjects; N = 521)

†Intrnlz H'type #	Tier	Endpoint	p-value	P(Event) by Haplo (Y/N) [N]	Odds Ratio
3-4	1 (≥3DI)	CVM	0.129	8.3%[36], 18.8%[485]	0.39 [0.12, 1.31]
3-4		AF/AFL/ACM	0.165	14.3%[28], 26.4%[375]	0.46 [0.16, 1.37]
3-4		CVM/HFH	0.004**	19.4%[36], 45.4%[485]	0.29 [0.12, 0.68]
3-4		Heart Failure Hosp	0.019*	16.7%[36], 36.9%[485]	0.34 [0.14, 0.84]
3-4		ACM/Tx	0.105	11.1%[36], 23.1%[485]	0.42 [0.14, 1.20]
3-4		Cardiovascular Hosp	0.049*	30.6%[36], 47.8%[485]	0.48 [0.23, 1.00]
3-4		ACM	0.083	8.3%[36], 20.8%[485]	0.35 [0.10, 1.15]
2	2 (2I)	CVM	0.51	16.2%[136], 18.7%[385]	0.84 [0.50, 1.42]
2		AF/AFL/ACM	0.26	21.5%[107], 27.0%[296]	0.74 [0.44, 1.25]
2		CVM/HFH	0.21	39.0%[136], 45.2%[385]	0.77 [0.52, 1.15]
2		Heart Failure Hosp	0.190	30.9%[136], 37.1%[385]	0.76 [0.50, 1.15]
2		ACM/Tx	0.31	19.1%[136], 23.4%[385]	0.77 [0.48, 1.26]
2		Cardiovascular Hosp	0.038*	39.0%[136], 49.4%[385]	0.66 [0.44, 0.98]
2		ACM	0.30	16.9%[136], 21.0%[385]	0.76 [0.46, 1.27]
0-1	3 (≥3DIR)	CVM	0.145	19.8%[349], 14.5%[172]	1.45 [0.88, 2.39]
0-1		AF/AFL/ACM	0.071	28.4%[268], 20.0%[135]	1.58 [0.96, 2.61]
0-1		CVM/HFH	0.005**	47.9%[349], 34.9%[172]	1.71 [1.17, 2.50]
0-1		Heart Failure Hosp	0.011*	39.3%[349], 27.9%[172]	1.67 [1.12, 2.48]
0-1		ACM/Tx	0.064	24.6%[349], 17.4%[172]	1.55 [0.97, 2.46]
0-1		Cardiovascular Hosp	0.003**	51.3%[349], 37.2%[172]	1.78 [1.22, 2.58]
0-1		ACM	0.053	22.3%[349], 15.1%[172]	1.62 [0.99, 2.63]



†Number of internalizing haplotypes

Main Effects of Internalization Tier within Bucindolol Patients (Unadjusted, All LVEF Subjects; N = 508)

†Intrnlz H'type #	Tier	Endpoint	p-value	P(Event) by Haplo (Y/N) [N]	Odds Ratio
3-4	1 (≥3DI)	CVM	0.46	8.6%[35], 12.9%[473]	0.63 [0.19, 2.13]
3-4		AF/AFL/ACM	0.79	23.1%[26], 20.9%[364]	1.14 [0.44, 2.93]
3-4		CVM/HFH	0.26	25.7%[35], 35.1%[473]	0.64 [0.29, 1.40]
3-4		Heart Failure Hosp	0.44	22.9%[35], 29.0%[473]	0.73 [0.32, 1.64]
3-4		ACM/Tx	0.62	14.3%[35], 17.5%[473]	0.78 [0.30, 2.08]
3-4		Cardiovascular Hosp	0.54	34.3%[35], 39.5%[473]	0.80 [0.39, 1.64]
3-4		ACM	0.73	14.3%[35], 16.5%[473]	0.84 [0.32, 2.24]
2	2 (2I)	CVM	0.72	11.7%[120], 12.9%[388]	0.89 [0.47, 1.68]
2		AF/AFL/ACM	0.23	16.7%[96], 22.4%[294]	0.69 [0.38, 1.26]
2		CVM/HFH	0.77	33.3%[120], 34.8%[388]	0.94 [0.61, 1.45]
2		Heart Failure Hosp	0.95	28.3%[120], 28.6%[388]	0.99 [0.63, 1.55]
2		ACM/Tx	0.44	15.0%[120], 18.0%[388]	0.80 [0.46, 1.41]
2		Cardiovascular Hosp	0.39	35.8%[120], 40.2%[388]	0.83 [0.54, 1.27]
2		ACM	0.46	14.2%[120], 17.0%[388]	0.81 [0.45, 1.43]
0-1	3 (≥3DIR)	CVM	0.46	13.3%[353], 11.0%[155]	1.25 [0.69, 2.25]
0-1		AF/AFL/ACM	0.33	22.4%[268], 18.0%[122]	1.31 [0.76, 2.26]
0-1		CVM/HFH	0.37	35.7%[353], 31.6%[155]	1.20 [0.80, 1.80]
0-1		Heart Failure Hosp	0.63	29.2%[353], 27.1%[155]	1.11 [0.73, 1.69]
0-1		ACM/Tx	0.33	18.4%[353], 14.8%[155]	1.30 [0.77, 2.17]
0-1		Cardiovascular Hosp	0.26	40.8%[353], 35.5%[155]	1.25 [0.85, 1.85]
0-1		ACM	0.39	17.3%[353], 14.2%[155]	1.26 [0.74, 2.14]



†Number of internalizing haplotypes

Main Effects of Treatment within Internalization Tier
(Unadjusted, All LVEF Subjects; N = 1029)

†Intrnlz H'type #	Tier	Endpoint	p-value	P(Event) by Rx (B/P) [N]	Odds Ratio
3-4	1 (≥3DI)	CVM	0.97	8.6%[35], 8.3%[36]	1.03 [0.19, 5.49]
3-4		AF/AFL/ACM	0.41	23.1%[26], 14.3%[28]	1.80 [0.45, 7.28]
3-4		CVM/HFH	0.53	25.7%[35], 19.4%[36]	1.43 [0.47, 4.40]
3-4		Heart Failure Hosp	0.51	22.9%[35], 16.7%[36]	1.48 [0.46, 4.82]
3-4		ACM/Tx	0.69	14.3%[35], 11.1%[36]	1.33 [0.33, 5.44]
3-4		Cardiovascular Hosp	0.74	34.3%[35], 30.6%[36]	1.19 [0.44, 3.21]
3-4		ACM	0.43	14.3%[35], 8.3%[36]	1.83 [0.40, 8.34]
2	2 (2I)	CVM	0.30	11.7%[120], 16.2%[136]	0.68 [0.33, 1.41]
2		AF/AFL/ACM	0.38	16.7%[96], 21.5%[107]	0.73 [0.36, 1.48]
2		CVM/HFH	0.35	33.3%[120], 39.0%[136]	0.78 [0.47, 1.31]
2		Heart Failure Hosp	0.66	28.3%[120], 30.9%[136]	0.88 [0.52, 1.52]
2		ACM/Tx	0.38	15.0%[120], 19.1%[136]	0.75 [0.39, 1.44]
2		Cardiovascular Hosp	0.60	35.8%[120], 39.0%[136]	0.87 [0.53, 1.45]
2		ACM	0.55	14.2%[120], 16.9%[136]	0.81 [0.41, 1.60]
0-1	3 (≥3DIR)	CVM	0.022*	13.3%[353], 19.8%[349]	0.62 [0.42, 0.93]
0-1		AF/AFL/ACM	0.113	22.4%[268], 28.4%[268]	0.73 [0.49, 1.08]
0-1		CVM/HFH	0.001**	35.7%[353], 47.9%[349]	0.60 [0.45, 0.82]
0-1		Heart Failure Hosp	0.005**	29.2%[353], 39.3%[349]	0.64 [0.47, 0.87]
0-1		ACM/Tx	0.045*	18.4%[353], 24.6%[349]	0.69 [0.48, 0.99]
0-1		Cardiovascular Hosp	0.005**	40.8%[353], 51.3%[349]	0.65 [0.49, 0.88]
0-1		ACM	0.093	17.3%[353], 22.3%[349]	0.73 [0.50, 1.05]



†Number of internalizing haplotypes


A. ACM/Tx, BEST: Maximum Double Internalization-resistant ADRB1 AND ADRB2 (≥4DIR)
LVEF ≥ 20
Probability of no ACM/Tx
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 3/86 (3.5%)
Placebo Group: 20/98 (20.4%)
Hazard Ratio = 0.17 (0.05,0.56)
P-value = 0.004
Days of Efficacy Follow-Up
B. AF/AFL/ACM, BEST: Maximum Double Internalization-resistant ADRB1 AND ADRB2 (≥4DIR)
LVEF ≥ 20
Probability of no AF/AFL/ACM
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 7/67 (10.4%)
Placebo Group: 19/76 (25%)
Hazard Ratio = 0.41 (0.17,0.97)
P-value = 0.042
Days of Efficacy Follow-Up
C. CVM/HFH, BEST: Maximum Double Internalization-resistant ADRB1 AND ADRB2 (≥4DIR)
LVEF ≥ 20
Probability of no CVM/HFH
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 19/86 (22.1%)
Placebo Group: 41/98 (41.8%)
Hazard Ratio = 0.49 (0.28,0.85)
P-value = 0.011
Days of Efficacy Follow-Up
D. CVH, BEST: Maximum Double Internalization-resistant ADRB1 AND ADRB2 (≥4DIR)
LVEF ≥ 20
Probability of no CVH
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 28/86 (32.6%)
Placebo Group: 53/98 (54.1%)
Hazard Ratio = 0.53 (0.33,0.84)
P-value = 0.007
Days of Efficacy Follow-Up

A.


CVM/HFH, BEST: ≥2DI, Blacks
Probability of no CVM/HFH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 13/33 (39.4%)
Placebo Group: 6/26 (23.1%)
Hazard Ratio = 1.75 (0.66,4.62)
P-value = 0.258


CVM/HFH, BEST: ≥2DI, Non-Blacks
Probability of no CVM/HFH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 18/57 (31.6%)
Placebo Group: 23/70 (32.9%)
Hazard Ratio = 0.84 (0.46,1.57)
P-value = 0.593


CVM/HFH, BEST: ≥2IR, Blacks
Probability of no CVM/HFH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 27/75 (36%)
Placebo Group: 35/71 (49.3%)
Hazard Ratio = 0.68 (0.41,1.13)
P-value = 0.139


CVM/HFH, BEST: ≥2IR, Non-Blacks
Probability of no CVM/HFH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 117/343 (34.1%)
Placebo Group: 163/354 (46%)
Hazard Ratio = 0.66 (0.52,0.84)
P-value = 0.001

B.


CVH, BEST: ≥2DI, Blacks
Probability of no CVH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 10/33 (30.3%)
Placebo Group: 8/26 (30.8%)
Hazard Ratio = 0.96 (0.38,2.44)
P-value = 0.932
CVH, BEST: ≥2DI Non-Blacks
Probability of no CVH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 24/57 (42.1%)
Placebo Group: 25/70 (35.7%)
Hazard Ratio = 1.11 (0.64,1.95)
P-value = 0.705
CVH, BEST: ≥2IR, Blacks
Probability of no CVH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 27/75 (36%)
Placebo Group: 36/71 (50.7%)
Hazard Ratio = 0.64 (0.39,1.06)
P-value = 0.084
CVH, BEST: ≥2IR, Non-Blacks
Probability of no CVH
Days of Efficacy Follow-Up
Bucindolol
Placebo
Event Rates:
Bucindolol Group: 138/343 (40.2%)
Placebo Group: 174/354 (49.2%)
Hazard Ratio = 0.76 (0.61,0.96)
P-value = 0.018


A.
Time 4 12 24
Bucindolol
Metoprolol
NT-proBNP Δ, (pg/ml)
1500
1000
500
0
-500
**
*
**
≥ 2DI
≥ 2IR
≥ 2DI
≥ 2IR
N=15
N=51
N=9
N=52
Internalization
C.
Time 4 12 24
Bucindolol
Metoprolol
Norepinephrine Δ, (pg/ml)
100
0
-100
-200
** † §
** † §
** †
≥ 2DI
≥ 2IR
≥ 2DI
≥ 2IR
N=15
N=55
N=8
N=56
Internalization
*P <0.05 vs. BsL
**P <0.01 vs. BsL
†P <0.05 vs. Metoprolol
§P <0.05 vs. ≥2DI
B.
Time 0 4 12 24
Bucindolol
Metoprolol
NT-proBNP (pg/ml)
2000
1000
0
**
*
**
≥ 2DI
≥ 2IR
≥ 2DI
≥ 2IR
N=15
N=51
N=9
N=52
Internalization
D.
Time 0 4 12 24
Bucindolol
Metoprolol
Norepinephrine (pg/ml)
800
600
400
200
0
** † §
** † §
** †
≥ 2DI
≥ 2IR
≥ 2IR
≥ 2IR
N=15
N=55
N=8
N=56
Internalization